Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Immunogenet ; 42(4): 294-6, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25976429

RESUMO

The new allelic variant HLA-B*38:55Q differs from the closest related B*38:01:01 by one nucleotide substitution at position 373 in exon 3 (TGC>CGC). This results in a difference of one amino acid at residue 101 of the HLA-B heavy chain, from a neutral-polar Cys to a basic-polar Arg, thus impairing disulphide bridge formation in the alpha-2 domain. This alteration of the secondary structure probably affects the maturation of the heavy chain and the level of surface expression, making the HLA-B*38:55Q undetectable by standard serological typing.


Assuntos
Alelos , Substituição de Aminoácidos/genética , Regulação da Expressão Gênica , Antígenos HLA-B/genética , Sequência de Aminoácidos/genética , Éxons , Antígenos HLA-B/biossíntese , Humanos , Dados de Sequência Molecular , Estrutura Secundária de Proteína , Alinhamento de Sequência , População Branca
2.
Transplant Proc ; 45(7): 2761-4, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24034042

RESUMO

Anti-HLA-specific donor antibodies induce rapid, irreversible destruction of the transplant (hyperacute rejection) that today happens rarely due to immunologic studies-prospective crossmatch-of patients awaiting the kidney graft. The usual approach for pretransplant donor/recipient evaluation is based on 2 methods: (1) the cytotoxic complement crossmatch (CDC) and (2) the flow cytometric crossmatch (FCX). The CDC crossmatch is positive when complement-fixing antibodies are present, an absolute contraindication to kidney transplantation. The more sensitive FCX-positive crossmatch detects low concentrations of unable to fix performed antibodies complement. It is an "index" of possible damage due to accelerated rejection. The target of our study was to develop a cytotoxic flow cytometry crossmatch (cFCX) that detected cytotoxic antibodies move sensitively than the traditional CDC method and also was less subjective and more standardized for interpretation studying sera from 23 patients; the cFCX showed the requested efficiency characteristics even in an emergency. In addition, the new method permited one to calculate a cutoff for positivity (average value of the negative control + 2 standard deviations), assuring an "objective" interpretation of the results that agreed with the CDC but was more sensitive and accurate allowing solution of ambiguous results for cases of "doubt"-positive CDC crossmatch. Furthermore, our aim was to correlate the effect of the strength of the anti-HLA antibodies determined by mean fluorescence intensity value of LabScreen Single Antigen beads with results of CDC, cFCX, and FCX methods.


Assuntos
Autoanticorpos/sangue , Citotoxicidade Imunológica , Citometria de Fluxo/métodos , Antígenos HLA/imunologia , Doadores de Tecidos , Humanos
3.
Transplant Proc ; 41(4): 1159-61, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19460505

RESUMO

Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.


Assuntos
Rejeição de Enxerto/imunologia , Antígeno Ki-1/sangue , Transplante de Rim , Adulto , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imunossupressores , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Transplantados , Transplante Homólogo , Uremia/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...